ACRS - Why Aclaris Therapeutics Stock Skyrocketed More Than 200% Today
Shares of Aclaris Therapeutics (NASDAQ: ACRS) surged on Tuesday, following the release of promising data regarding its experimental treatment for rheumatoid arthritis.
As of 12:20 a.m. EST today, the pharmaceutical company's stock price was up 212%.
Aclaris Therapeutics announced preliminary results from a phase 2a clinical trial of ATI-450, an investigational oral MK2 inhibitor, in patients with moderate to severe rheumatoid arthritis. ATI-450 reportedly demonstrated a "marked and sustained reduction" in disease-activity scores in the placebo-controlled study. It was also shown to be generally well tolerated, with no serious adverse events reported during the trial.
For further details see:
Why Aclaris Therapeutics Stock Skyrocketed More Than 200% Today